Haselmeier manufacture disposable injection device after receiving allowance

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/macky_ch)
(Image: Getty/macky_ch)

Related tags: Drug delivery, Drug delivery systems, Injection, autoinjector, Manufacturing, Germany

Haselmeier to provide assembly, labeling, and packaging services for its drug-device combination products following recent permission given to Germany-site.

As of last week, Haselmeir will begin the manufacture its own drug-device combination pharmaceuticals, D-Flex pen, at its Buchen, Germany site, after having received manufacturing allowance in December 2018.

The D-Flex pen was designed specifically to allow Haselmeier’s clients to use the same disposable injection device from the clinical trial stage to their commercial supply.

Konrad Betzler, chief quality officer at Haselmeier, told us that with the manufacturing site up and running, “[it] will support Haselmeier with bringing its newly developed D-Flex pen to the market as a fully assembled and labeled combination product.”

The newly combined capabilities of device and combination product manufacturing is expected to double the output, including that of the company’s D-Flex pen, from the site within the next 12 to 24 months.

“The manufacturing allowance is also a plus in supporting the assembly of connected devices, consisting of the mechanical pen, drug cartridge, and electronics, currently being developed by Haselmeier and some of its clients,”​ Betzler added.

Haselmeier recently partnered​ with Common Sensing to develop smart connected monitoring and support solutions for injectable medicines users.

Through the partnership, Haselmeier’s subcutaneous drug delivery injection systems will be combined with Common Sensing Gocap injector monitoring technology to provide a smart disposable injector pen platform. 

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more